Welcome to the e-CCO Library Archive!

Filter:
P041. Piroxicam-accelerated colitis in interleukin-10 knock out mice – a “new” model of human inflammatory bowel disease
Authors:

K. Holgersen1, P.H. Kvist2, A.K. Hansen3, T.L. Holm4, 1Novo Nordisk-LIFE In Vivo Pharmacology Centre, Frederiksberg, Denmark, 2Novo Nordisk A/S, Department of Histology, Måløv, Denmark, 3University of Copenhagen, Department of Veterinary Disease Biology, Frederiksberg, Denmark, 4Novo Nordisk A/S, Department of Immunopharmacology, Måløv, Denmark

P041. Pregnane X receptor is an unlikely therapeutic target for inflammatory bowel disease
P041

Mesenchymal stem cells protect from acute dextran sulphate sodium-induced colitis by attenuating function of antigen presenting cells

Authors:

V. Volarevic*, A. Nikolic, B. Simovic Markovic, M. Gazdic, I. Djordjevic, M. Dasic, N. Arsenijevic, M.L. Lukic

Faculty of Medical Sciences University of Kragujevac, Immunology, Kragujevac, Serbia

P042.

Microbiota stability in vivo and in vitro

Authors:

F.T. Hegge1, H. Vebø1, E. Ciemniejewska1, C. Frøyland1, S. Kreso1, M. Sekelja1, A. Røseth2, C. Casen1, 1Genetic Analysis AS, Development, Oslo, Norway, 2Lovisenberg Diakonale Hospital, Unger-Vetlesens Institute, Oslo, Norway

P042. Investigation of NOD2 signalling in Crohn's disease
P042. Patients' preferences when selecting biologics for inflammatory bowel disease
Authors:

E. Tsiaousi1, C. Tzathas2, C. Zeglinas2, G. Michalopoulos2, G. Kouklakis3, A. Babali3, S. Polyzos1, G. Tsarouchas1, C. Stergiopoulos1, S. Michael1, K. Anastasiadou1, J. Kountouras1, 1Aristotle University of Thessaloniki, 2nd Medical Clinic, Thessaloniki, Greece, 2Tzanio General Hospital, Piraeus, Gatsroenterological Clinic, Athens, Greece, 3Dimokrition University of Thrace, Gatsroenterological Clinic, Alexandroupolis, Greece

P042. The effect of infliximab and adalimumab treatment on angiogenic factor levels in patients with inflammatory bowel disease (IBD)
P042

Response to corticosteroids in Ulcerative Colitis may be related to modulation of mTOR signaling pathway genes by microRNAs

Authors:

J.E. Naves*1, J. Manye1, 2, V. Loren1, M. Mañosa2, 3, I. Moret2, 4, A. García-Jaraquemada1, G. Bastida2, 4, B. Beltrán2, 4, E. Cabré2, 3, E. Domènech2, 3

1Germans Trias i Pujol Health Sciences Research Institute, Gastroenterology Department, Badalona, Spain, 2Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, CIBERehd, , Spain, 3Hospital Universitari Germans Trias i Pujol, Gastroenterology Department, Badalona, Spain, 4Hospital La Fe, Gastroenterology Unit, Valencia, Spain

P043.

Microbial balances altered by restriction of dietary iron ameliorated immune-mediated colitis

Authors:

T. Toyonaga1, M. Matsuura2, H. Nakase2, S. Yamada2, N. Minami2, Y. Honzawa2, T. Yoshino2, K. Okazaki1, T. Chiba2, 1Kansai Medical University, Department of Gastroenterology and Hepatology, Osaka, Japan, 2Kyoto University Hospital, Department of Gastroenterology and Hepatology, Kyoto, Japan

P043. Induction of mucosal inflammation by Damage-Associated Molecular Patterns (DAMPs): Intestinal Epithelial Cells (IEC)-derived IL‑1α as a new player in the pathogenesis of IBD
P043. MMPs in pouch in pediatric onset IBD – Diagnostic clues and markers for inflammation
P043. PRKCDBP, a new transcriptional target of TNF-alpha signaling pathway in ulcerative colitis
Authors:

H.J. Kim1, C.K. Lee1, K.H. Kang1, 1Kyung Hee University Hospital, Internal Medicine, Seoul, South Korea

P043

Immunohistochemical expression of angio and lymphangiogenic factors in colonic mucosa of patients with inflammatory bowel disease.

Authors:

P.M. Linares1, M. Chaparro1, A. Algaba2, I. Guerra2, F. Bermejo2, J.P. Gisbert*1

1Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain, 2Hospital Universitario de Fuenlabrada, Gastroenterology Unit, Madrid, Spain

P044.

MicroRNA expression in ileal inflammatory bowel disease correlates with disease behavior

Authors:

S. Ben-Shachar1, H. Yanai2, H. Elad2, L. Baram2, H. Sherman Horev2, A. Ofer2, E. Brazowski3, H. Tulchinsky4, M. Pasmanik-Chor5, N. Shomron6, I. Dotan2, 1Tel Aviv Medical Center affiliated to Sackler Faculty of Medicine, Tel Aviv university, Genetic institute, Tel Aviv, Israel, 2Tel Aviv Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel, 3Tel Aviv Sourasky Medical Center, affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Department of Pathology, Tel Aviv, Israel, 4Tel Aviv Medical Center, affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Proctology Unit, Department of Surgery, Tel Aviv, Israel, 5Tel Aviv University, Tel Aviv, Israel, Bioinformatics unit, G.S.W. Faculty of Life Sciences, Tel Aviv, Israel, 6Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel

P044. Identification of a novel role for interleukin-27 as mediator of intestinal epithelial barrier protection acting via differential STAT signalling and induction of antibacterial and anti-inflammatory proteins
P044. Novel image using hydrogen sulfide multiphoton probe in the mucosal tissue of ulcerative colitis patients
Authors:

E.S. Kim1, Y.T. Jeen1, B. Keum1, H.J. Chun1, B.J. Lee1, J.S. Koo1, R.S. Choung1, J.H. Choi1, B.R. Cho2, 1Korea University College of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul, South Korea, 2Korea University, Department of Chemistry, Seoul, South Korea

P044. OPG circulating levels are reduced by infliximab treatment and correlate to CRP levels
P044

Systematic Review of the use of metabonomics in inflammatory bowel disease (IBD)

Authors:

N.S. Ding*, N. A Yassin, A. Hart

St Mark's Hospital, Inflammatory Bowel Disease Unit, London, United Kingdom

P045.

Macrophage subtypes disrupt the epithelium via deregulated tight junctions and induction of apoptosis

Authors:

D. Lissner, M. Schumann, C. May, L.-I. Kredel, A. Batra, A. Kühl, J.-D. Schulzke, B. Siegmund, Charite, Hepatology and Gastroenterology Campus Benjamin Franklin, Berlin, Germany

P045. Direct effects of infliximab (IFX) on intestinal mucosa: Exploring mechanisms of mucosal healing